What We Are Watching
Life Sciences · Healthcare
The Platform Shift in Drug Discovery Is Happening. The Infrastructure for It Is Not Ready.
Gene editing and cell therapy are transitioning from experimental to commercial. The biology is proven. The manufacturing, logistics, and supply chain infrastructure required to deliver these therapies at commercial scale does not yet exist. That gap is the opportunity.
2/28/2026
What We Are Watching is Vaxa's signal intelligence column. We identify markets, technologies, and structural shifts already in motion but may not yet reached the corporate strategy conversation.
highlights
01
Gene editing and cell therapy are transitioning from experimental to commercial at a pace most corporate strategy functions have not yet absorbed
02
The platform shift affects not just pharmaceutical companies but technology, industrial, and agricultural players
03
The FDA approval pipeline for gene therapies has accelerated — over 30 cell and gene therapy approvals in the last five years
04
The manufacturing and supply chain infrastructure for these therapies does not yet exist at commercial scale
05
The companies that will capture value are not necessarily the ones developing the therapies — the infrastructure opportunity is significant and underattended
Signal
Gene editing and cell therapy have been described as the future of medicine for long enough that the description has lost some of its urgency. That gap between promise and commercial reality is closing. The pace of FDA approvals for cell and gene therapies has accelerated materially over the past five years.
CRISPR-based gene editing has moved from a laboratory tool to a clinical platform. The first CRISPR therapy for sickle cell disease received FDA approval in late 2023 — validating a platform that can in principle be applied to any condition with a defined genetic target.
The platform shift in drug discovery — from chemistry-first to biology-first — is the most significant structural change in the pharmaceutical industry in a generation. Most corporate strategy functions outside healthcare have not yet absorbed what it means for them.
Pattern
The strategic significance of gene editing and cell therapy extends well beyond pharmaceutical companies. The enabling technologies — DNA synthesis, gene sequencing, protein engineering, bioreactor design — have applications across agriculture, industrial biotechnology, materials science, and food production advancing in parallel with clinical applications.
In industrial biotechnology, engineered microorganisms are being used to produce materials, chemicals, and fuels through biological processes that compete with petrochemical and mining supply chains.
The therapies get the headlines. The infrastructure to make, store, and deliver them at scale is where the actual commercial opportunity — and the actual bottleneck — sits.
Mechanism
The most significant near-term opportunity in the gene editing and cell therapy landscape is not in the therapies themselves. It is in the infrastructure required to manufacture, store, distribute, and deliver them at commercial scale.
Cell therapy manufacturing is currently characterized by small-batch, highly manual processes that are difficult to scale without sacrificing quality. The facilities, equipment, and trained workforce required do not yet exist at sufficient scale.
A platform shift this size does not wait for the supporting infrastructure to catch up. It just exposes, very publicly, who built it in time.
Implication
The infrastructure gap is not just a manufacturing problem. It is a logistics, regulatory, reimbursement, and workforce problem simultaneously. Each represents an opportunity for companies with relevant capabilities who are paying attention to the signal.
A platform shift creates more opportunity in the picks and shovels than in the gold itself.
Question
For companies outside pharmaceuticals — in logistics, manufacturing, workforce training, and specialty real estate — the gene editing and cell therapy platform shift is not a healthcare story to watch from the sidelines. It is an infrastructure buildout with real commercial demand attached, arriving on a timeline that rewards the companies who move before the bottleneck becomes obvious to everyone else.
The companies watching from outside pharma are the ones with the least excuse for being surprised later.
The question to ask.
Which of the enabling infrastructure requirements for gene editing and cell therapy commercialization overlaps with capabilities your organization already has — and are you positioned to see that adjacency before it becomes obvious?